Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
Open Access
- 16 May 2019
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (7) , 1771-1777
Abstract
Introduction Infections due to Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are associated with increased morbidity and high mortality. Meropenem–vaborbactam (MV) is a novel β-lactam/β-lactamase inhibitor combination active against KPC-producing Enterobacteriaceae. The aim of this post hoc analysis of the TANGO-II randomized controlled trial was to assess the efficacy of MV versus best available therapy (BAT) in the subgroup of patients without prior antimicrobial failure. Methods The primary outcome measure was clinical cure at the test of cure (TOC). Secondary outcome measures included (1) clinical cure at the end of therapy (EOT), (2) microbiological cure at TOC, (3) microbiological cure at EOT, and (4) 28-day all-cause mortality. Results First-line MV was associated with a 42.9% absolute increase in clinical cure rate at TOC (95% confidence intervals [CI] 13.7–72.1) in comparison with first-line BAT. A 49.3% absolute increase in clinical cure rate at EOT (95% CI 20.8–77.7), a 42.6% absolute increase in microbiological cure rate at EOT (95% CI 13.4–71.8), and a 36.2% absolute increase in microbiologic cure rate at TOC (95% CI 5.9–66.6) were also observed, in addition to a 29.0% absolute reduction in mortality (95% CI − 54.3 to − 3.7). Overall, fewer adverse events were observed in the MV group than in the BAT group. Conclusion MV was superior to BAT in the subgroup of patients with serious carbapenem-resistant Enterobacteriaceae (CRE) infections and no prior antimicrobial failure, with very high rates of clinical success, and was well tolerated. Post approval and real-world studies remain essential to clearly define the most appropriate population for early, empirical MV coverage, in accordance with antimicrobial stewardship principles. Funding The Medicines Company.Keywords
Funding Information
- The Medicines Company (1)
This publication has 13 references indexed in Scilit:
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract InfectionJAMA, 2018
- Management of KPC-producing Klebsiella pneumoniae infectionsClinical Microbiology and Infection, 2018
- Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studiesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsisBMC Infectious Diseases, 2017
- Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical TrialsOpen Forum Infectious Diseases, 2017
- Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control studyClinical Microbiology and Infection, 2015
- Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre studyJournal of Antimicrobial Chemotherapy, 2015
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases2015
- A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantationClinical Microbiology and Infection, 2015
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of CarbapenemsAntimicrobial Agents and Chemotherapy, 2014